@article {Danis172, author = {Ronald Danis and Megan M McLaughlin and Michael Tolentino and Giovanni Staurenghi and Li Ye and Chun-Fang Xu and Robert Y Kim and Mark W Johnson and for the Pazopanib Eye Drops Study Group}, editor = {Reichel, Elias and Glazer, Louis and Ciulla, Thomas and Menchini, Ugo and Vaona, Paola and Pearlman, Joel and Midena, Edoardo and Introini, Ugo and Arnold, Jennifer and Boyer, David and Wong, Tien and Hudson, Henry and Guymer, Robyn and Bernstein, Paul and Leys, Anita and Berger, Brian and Greven, Craig and Mitchell, Paul and Constable, Ian}, title = {Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration}, volume = {98}, number = {2}, pages = {172--178}, year = {2014}, doi = {10.1136/bjophthalmol-2013-303117}, publisher = {BMJ Publishing Group Ltd}, abstract = {Aims To evaluate pazopanib eye drops in patients with subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Methods 70 patients with minimally classic or occult subfoveal choroidal neovascularisation were randomly assigned to 5 mg/mL TID, 2 mg/mL TID, and 5 mg/mL QD pazopanib eye drops for 28 days in a multicentre, double-masked trial with an optional safety extension for up to 5 additional months. The primary outcomes were central retinal thickness (CRT) and best-corrected visual acuity (BCVA) at Day 29. Results No significant decrease from baseline in CRT was observed overall; however, an exploratory analysis showed improvement in CRT (mean decrease of 89 μm) in patients with the CFH TT genotype who received 5 mg/mL TID (p=0.01, n=5). Mean increases in BCVA were observed in the 5 mg/mL TID overall (4.32 letters (p=0.002, n=26)) and in those that with CFH Y402H TT (6.96 letters (p=0.02, n=5)) and CT (4.09 letters (p=0.05, n=9)) genotypes. No safety signals that precluded continued investigation were detected. Conclusions 5 mg/mL pazopanib eye drops resulted in mean improvement in BCVA at Day 29 and improvements in vision. However, improvement in macular oedema for age-related macular degeneration was found only in the subset of subjects with the CFH Y402H TT genotype, warranting further investigation.}, issn = {0007-1161}, URL = {https://bjo.bmj.com/content/98/2/172}, eprint = {https://bjo.bmj.com/content/98/2/172.full.pdf}, journal = {British Journal of Ophthalmology} }